165 related articles for article (PubMed ID: 34929424)
1. Effects of chemotherapy on contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers: A nationwide cohort study.
Akdeniz D; van Barele M; Heemskerk-Gerritsen BAM; Steyerberg EW; Hauptmann M; ; van de Beek I; van Engelen K; Wevers MR; Gómez García EB; Ausems MGEM; Berger LPV; van Asperen CJ; Adank MA; Collée MJ; Stommel-Jenner DJ; Jager A; Schmidt MK; Hooning MJ
Breast; 2022 Feb; 61():98-107. PubMed ID: 34929424
[TBL] [Abstract][Full Text] [Related]
2. Contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers in a large cohort of unselected Chinese breast cancer patients.
Su L; Xu Y; Ouyang T; Li J; Wang T; Fan Z; Fan T; Lin B; Xie Y
Int J Cancer; 2020 Jun; 146(12):3335-3342. PubMed ID: 32037537
[TBL] [Abstract][Full Text] [Related]
3. Impact of Age at Primary Breast Cancer on Contralateral Breast Cancer Risk in BRCA1/2 Mutation Carriers.
van den Broek AJ; van 't Veer LJ; Hooning MJ; Cornelissen S; Broeks A; Rutgers EJ; Smit VT; Cornelisse CJ; van Beek M; Janssen-Heijnen ML; Seynaeve C; Westenend PJ; Jobsen JJ; Siesling S; Tollenaar RA; van Leeuwen FE; Schmidt MK
J Clin Oncol; 2016 Feb; 34(5):409-18. PubMed ID: 26700119
[TBL] [Abstract][Full Text] [Related]
4. Adjuvant systemic therapy for breast cancer in BRCA1/BRCA2 mutation carriers in a population-based study of risk of contralateral breast cancer.
Reding KW; Bernstein JL; Langholz BM; Bernstein L; Haile RW; Begg CB; Lynch CF; Concannon P; Borg A; Teraoka SN; Törngren T; Diep A; Xue S; Bertelsen L; Liang X; Reiner AS; Capanu M; Malone KE;
Breast Cancer Res Treat; 2010 Sep; 123(2):491-8. PubMed ID: 20135344
[TBL] [Abstract][Full Text] [Related]
5. Contralateral Breast Cancer Risk Among Carriers of Germline Pathogenic Variants in
Yadav S; Boddicker NJ; Na J; Polley EC; Hu C; Hart SN; Gnanaolivu RD; Larson N; Holtegaard S; Huang H; Dunn CA; Teras LR; Patel AV; Lacey JV; Neuhausen SL; Martinez E; Haiman C; Chen F; Ruddy KJ; Olson JE; John EM; Kurian AW; Sandler DP; O'Brien KM; Taylor JA; Weinberg CR; Anton-Culver H; Ziogas A; Zirpoli G; Goldgar DE; Palmer JR; Domchek SM; Weitzel JN; Nathanson KL; Kraft P; Couch FJ
J Clin Oncol; 2023 Mar; 41(9):1703-1713. PubMed ID: 36623243
[TBL] [Abstract][Full Text] [Related]
6. Contralateral breast cancer after radiotherapy among BRCA1 and BRCA2 mutation carriers: a WECARE study report.
Bernstein JL; Thomas DC; Shore RE; Robson M; Boice JD; Stovall M; Andersson M; Bernstein L; Malone KE; Reiner AS; Lynch CF; Capanu M; Smith SA; Tellhed L; Teraoka SN; Begg CB; Olsen JH; Mellemkjaer L; Liang X; Diep AT; Borg A; Concannon P; Haile RW;
Eur J Cancer; 2013 Sep; 49(14):2979-85. PubMed ID: 23706288
[TBL] [Abstract][Full Text] [Related]
7. Breast cancer risk in BRCA1/2 mutation carriers and noncarriers under prospective intensified surveillance.
Engel C; Fischer C; Zachariae S; Bucksch K; Rhiem K; Giesecke J; Herold N; Wappenschmidt B; Hübbel V; Maringa M; Reichstein-Gnielinski S; Hahnen E; Bartram CR; Dikow N; Schott S; Speiser D; Horn D; Fallenberg EM; Kiechle M; Quante AS; Vesper AS; Fehm T; Mundhenke C; Arnold N; Leinert E; Just W; Siebers-Renelt U; Weigel S; Gehrig A; Wöckel A; Schlegelberger B; Pertschy S; Kast K; Wimberger P; Briest S; Loeffler M; Bick U; Schmutzler RK;
Int J Cancer; 2020 Feb; 146(4):999-1009. PubMed ID: 31081934
[TBL] [Abstract][Full Text] [Related]
8. Adjuvant radiotherapy for primary breast cancer in BRCA1 and BRCA2 mutation carriers and risk of contralateral breast cancer with special attention to patients irradiated at younger age.
Drooger J; Akdeniz D; Pignol JP; Koppert LB; McCool D; Seynaeve CM; Hooning MJ; Jager A
Breast Cancer Res Treat; 2015 Nov; 154(1):171-80. PubMed ID: 26467044
[TBL] [Abstract][Full Text] [Related]
9. Tamoxifen and risk of contralateral breast cancer among women with inherited mutations in BRCA1 and BRCA2: a meta-analysis.
Xu L; Zhao Y; Chen Z; Wang Y; Chen L; Wang S
Breast Cancer; 2015 Jul; 22(4):327-34. PubMed ID: 26022977
[TBL] [Abstract][Full Text] [Related]
10. Cancer risks for BRCA1 and BRCA2 mutation carriers: results from prospective analysis of EMBRACE.
Mavaddat N; Peock S; Frost D; Ellis S; Platte R; Fineberg E; Evans DG; Izatt L; Eeles RA; Adlard J; Davidson R; Eccles D; Cole T; Cook J; Brewer C; Tischkowitz M; Douglas F; Hodgson S; Walker L; Porteous ME; Morrison PJ; Side LE; Kennedy MJ; Houghton C; Donaldson A; Rogers MT; Dorkins H; Miedzybrodzka Z; Gregory H; Eason J; Barwell J; McCann E; Murray A; Antoniou AC; Easton DF;
J Natl Cancer Inst; 2013 Jun; 105(11):812-22. PubMed ID: 23628597
[TBL] [Abstract][Full Text] [Related]
11. Clinical and molecular characterization of BRCA-associated breast cancer: results from the DBCG.
Soenderstrup IMH; Laenkholm AV; Jensen MB; Eriksen JO; Gerdes AM; Hansen TVO; Kruse TA; Larsen MJ; Pedersen IS; Rossing M; Thomassen M; Ejlertsen B
Acta Oncol; 2018 Jan; 57(1):95-101. PubMed ID: 29164974
[TBL] [Abstract][Full Text] [Related]
12. BRCA-CRisk: A Contralateral Breast Cancer Risk Prediction Model for
Sun J; Chu F; Pan J; Zhang Y; Yao L; Chen J; Hu L; Zhang J; Xu Y; Wang X; Cao W; Xie Y
J Clin Oncol; 2023 Feb; 41(5):991-999. PubMed ID: 36480783
[TBL] [Abstract][Full Text] [Related]
13. Tamoxifen and risk of contralateral breast cancer for BRCA1 and BRCA2 mutation carriers.
Phillips KA; Milne RL; Rookus MA; Daly MB; Antoniou AC; Peock S; Frost D; Easton DF; Ellis S; Friedlander ML; Buys SS; Andrieu N; Noguès C; Stoppa-Lyonnet D; Bonadona V; Pujol P; McLachlan SA; John EM; Hooning MJ; Seynaeve C; Tollenaar RA; Goldgar DE; Terry MB; Caldes T; Weideman PC; Andrulis IL; Singer CF; Birch K; Simard J; Southey MC; Olsson HL; Jakubowska A; Olah E; Gerdes AM; Foretova L; Hopper JL
J Clin Oncol; 2013 Sep; 31(25):3091-9. PubMed ID: 23918944
[TBL] [Abstract][Full Text] [Related]
14. Toxicity of (neo)adjuvant chemotherapy for BRCA1- and BRCA2-associated breast cancer.
Drooger JC; Heemskerk-Gerritsen BAM; Smallenbroek N; Epskamp C; Seynaeve CM; Jager A
Breast Cancer Res Treat; 2016 Apr; 156(3):557-566. PubMed ID: 27060914
[TBL] [Abstract][Full Text] [Related]
15. Endometrial Cancer Risk in Women With Germline BRCA1 or BRCA2 Mutations: Multicenter Cohort Study.
de Jonge MM; de Kroon CD; Jenner DJ; Oosting J; de Hullu JA; Mourits MJE; Gómez Garcia EB; Ausems MGEM; Margriet Collée J; van Engelen K; van de Beek I; ; Smit VTHBM; Rookus MA; de Bock GH; van Leeuwen FE; Bosse T; Dekkers OM; van Asperen CJ
J Natl Cancer Inst; 2021 Sep; 113(9):1203-1211. PubMed ID: 33710348
[TBL] [Abstract][Full Text] [Related]
16. The predictive ability of the 313 variant-based polygenic risk score for contralateral breast cancer risk prediction in women of European ancestry with a heterozygous BRCA1 or BRCA2 pathogenic variant.
Lakeman IMM; van den Broek AJ; Vos JAM; Barnes DR; Adlard J; Andrulis IL; Arason A; Arnold N; Arun BK; Balmaña J; Barrowdale D; Benitez J; Borg A; Caldés T; Caligo MA; Chung WK; Claes KBM; ; ; Collée JM; Couch FJ; Daly MB; Dennis J; Dhawan M; Domchek SM; Eeles R; Engel C; Evans DG; Feliubadaló L; Foretova L; Friedman E; Frost D; Ganz PA; Garber J; Gayther SA; Gerdes AM; Godwin AK; Goldgar DE; Hahnen E; Hake CR; Hamann U; Hogervorst FBL; Hooning MJ; Hopper JL; Hulick PJ; Imyanitov EN; ; ; ; Isaacs C; Izatt L; Jakubowska A; James PA; Janavicius R; Jensen UB; Jiao Y; John EM; Joseph V; Karlan BY; Kets CM; Konstantopoulou I; Kwong A; Legrand C; Leslie G; Lesueur F; Loud JT; Lubiński J; Manoukian S; McGuffog L; Miller A; Gomes DM; Montagna M; Mouret-Fourme E; Nathanson KL; Neuhausen SL; Nevanlinna H; Yie JNY; Olah E; Olopade OI; Park SK; Parsons MT; Peterlongo P; Piedmonte M; Radice P; Rantala J; Rennert G; Risch HA; Schmutzler RK; Sharma P; Simard J; Singer CF; Stadler Z; Stoppa-Lyonnet D; Sutter C; Tan YY; Teixeira MR; Teo SH; Teulé A; Thomassen M; Thull DL; Tischkowitz M; Toland AE; Tung N; van Rensburg EJ; Vega A; Wappenschmidt B; Devilee P; van Asperen CJ; Bernstein JL; Offit K; Easton DF; Rookus MA; Chenevix-Trench G; Antoniou AC; Robson M; Schmidt MK
Genet Med; 2021 Sep; 23(9):1726-1737. PubMed ID: 34113011
[TBL] [Abstract][Full Text] [Related]
17. Cumulative risk of second primary contralateral breast cancer in BRCA1/BRCA2 mutation carriers with a first breast cancer: A systematic review and meta-analysis.
Molina-Montes E; Pérez-Nevot B; Pollán M; Sánchez-Cantalejo E; Espín J; Sánchez MJ
Breast; 2014 Dec; 23(6):721-42. PubMed ID: 25467311
[TBL] [Abstract][Full Text] [Related]
18. High risk of contralateral breast carcinoma in women with hereditary/familial non-BRCA1/BRCA2 breast carcinoma.
Shahedi K; Emanuelsson M; Wiklund F; Gronberg H
Cancer; 2006 Mar; 106(6):1237-42. PubMed ID: 16475207
[TBL] [Abstract][Full Text] [Related]
19. Common alleles at 6q25.1 and 1p11.2 are associated with breast cancer risk for BRCA1 and BRCA2 mutation carriers.
Antoniou AC; Kartsonaki C; Sinilnikova OM; Soucy P; McGuffog L; Healey S; Lee A; Peterlongo P; Manoukian S; Peissel B; Zaffaroni D; Cattaneo E; Barile M; Pensotti V; Pasini B; Dolcetti R; Giannini G; Putignano AL; Varesco L; Radice P; Mai PL; Greene MH; Andrulis IL; Glendon G; Ozcelik H; Thomassen M; Gerdes AM; Kruse TA; Birk Jensen U; Crüger DG; Caligo MA; Laitman Y; Milgrom R; Kaufman B; Paluch-Shimon S; Friedman E; Loman N; Harbst K; Lindblom A; Arver B; Ehrencrona H; Melin B; ; Nathanson KL; Domchek SM; Rebbeck T; Jakubowska A; Lubinski J; Gronwald J; Huzarski T; Byrski T; Cybulski C; Gorski B; Osorio A; Ramón y Cajal T; Fostira F; Andrés R; Benitez J; Hamann U; Hogervorst FB; Rookus MA; Hooning MJ; Nelen MR; van der Luijt RB; van Os TA; van Asperen CJ; Devilee P; Meijers-Heijboer HE; Gómez Garcia EB; ; Peock S; Cook M; Frost D; Platte R; Leyland J; Evans DG; Lalloo F; Eeles R; Izatt L; Adlard J; Davidson R; Eccles D; Ong KR; Cook J; Douglas F; Paterson J; Kennedy MJ; Miedzybrodzka Z; ; Godwin A; Stoppa-Lyonnet D; Buecher B; Belotti M; Tirapo C; Mazoyer S; Barjhoux L; Lasset C; Leroux D; Faivre L; Bronner M; Prieur F; Nogues C; Rouleau E; Pujol P; Coupier I; Frénay M; ; Hopper JL; Daly MB; Terry MB; John EM; Buys SS; Yassin Y; Miron A; Goldgar D; ; Singer CF; Tea MK; Pfeiler G; Dressler AC; Hansen Tv; Jønson L; Ejlertsen B; Barkardottir RB; Kirchhoff T; Offit K; Piedmonte M; Rodriguez G; Small L; Boggess J; Blank S; Basil J; Azodi M; Toland AE; Montagna M; Tognazzo S; Agata S; Imyanitov E; Janavicius R; Lazaro C; Blanco I; Pharoah PD; Sucheston L; Karlan BY; Walsh CS; Olah E; Bozsik A; Teo SH; Seldon JL; Beattie MS; van Rensburg EJ; Sluiter MD; Diez O; Schmutzler RK; Wappenschmidt B; Engel C; Meindl A; Ruehl I; Varon-Mateeva R; Kast K; Deissler H; Niederacher D; Arnold N; Gadzicki D; Schönbuchner I; Caldes T; de la Hoya M; Nevanlinna H; Aittomäki K; Dumont M; Chiquette J; Tischkowitz M; Chen X; Beesley J; Spurdle AB; ; Neuhausen SL; Chun Ding Y; Fredericksen Z; Wang X; Pankratz VS; Couch F; Simard J; Easton DF; Chenevix-Trench G;
Hum Mol Genet; 2011 Aug; 20(16):3304-21. PubMed ID: 21593217
[TBL] [Abstract][Full Text] [Related]
20. Mammography screening and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers: a prospective study.
Giannakeas V; Lubinski J; Gronwald J; Moller P; Armel S; Lynch HT; Foulkes WD; Kim-Sing C; Singer C; Neuhausen SL; Friedman E; Tung N; Senter L; Sun P; Narod SA
Breast Cancer Res Treat; 2014 Aug; 147(1):113-8. PubMed ID: 25082516
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
